Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Viking Therapeutics, Inc.NASDAQ: VKTX
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow grows, but more slowly than its trailing trend
Q2 FY2026 free cash flow of $125.17M (cash outflow) rose 166.0% year over year, behind the +174.3% change in trailing-twelve-month free cash flow. Sequentially, it rose 9.8% from the prior quarter. Over 3 fiscal years it compounded at +79.2% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +166.0% toward the trailing-twelve-month pace of +174.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (278.69M) USD
- Year-over-year change
- -217.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (278.69M) | -217.4% |
| FY2024 | 2024-12-31 | (87.79M) | -19.6% |
| FY2023 | 2023-12-31 | (73.38M) | -51.6% |
| FY2022 | 2022-12-31 | (48.4M) | -1.7% |
| FY2021 | 2021-12-31 | (47.59M) | — |
Free Cash Flow vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 free cash flow of $418.44M is the largest of the 7 companies compared; the peer median is $110.81M.
- Its year-over-year change of +174.3% is the highest of 6, against a peer median of -33.1%.
- Over three fiscal years its annual growth of +79.2% compares with a peer median of +18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $418.44M | +174.3% | +79.2% | — | |
| LTM Jun 2026 | $206.29M | -33.1% | -5.5% | 16.1% | |
| LTM Jun 2026 | $143.72M | +15.6% | — | 2018.3% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $122.3M | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $99.33M | +25.9% | +51.5% | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $77.59M | -175.2% | — | 80.6% |
| LTM Mar 2026 | $10.41M | -56.0% | +18.3% | 28.3% | |
| Peer median (excluding VKTX) | $110.81M | -33.1% | +18.3% | 54.4% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 8.67M | 16.75M | 29.71M | 40.82M |
| Change in Working Capital | (2.93M) | 10.19M | 3.55M | 9.36M | 48.98M |
| Accounts Receivables | 1.18M | 614K | 321K | 1.2M | 5.08M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.54M) | 7.09M | (1.02M) | 2.3M | 43.44M |
| Other Working Capital | (1.56M) | 2.49M | 4.25M | 5.86M | 464K |
| Other Non-Cash Items | 3.94M | 1.32M | (8.07M) | (17.25M) | (9.27M) |
| Operating Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (168.02M) | (121.43M) | (478.3M) | (1.11B) | (418.04M) |
| Sales of Investments | 205.98M | 176.18M | 299.22M | 560M | 759.43M |
| Other Investing Activities | 0 | 54.75K | 0 | 0 | 0 |
| Investing Cash Flow | 37.96M | 54.75M | (179.09M) | (553.37M) | 341.39M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 7.59M | 0 | 269.76M | 597.09M | 2.49M |
| Common Stock Repurchased | 0 | (6.8M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (707K) | 12.49M | 1.62M | 15.37M | 73.95M |
| Financing Cash Flow | 6.88M | 4.16M | 271.38M | 612.46M | 76.44M |
| Effect of Forex Changes | 0 | (258K) | (30K) | (148K) | (8K) |
| Net Change in Cash | (2.75M) | 10.26M | 18.88M | (28.84M) | 139.13M |
| Free Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.